Santen Pharmaceutical (OTCMKTS:SNPHY) Shares Gap Down – Here’s Why

Shares of Santen Pharmaceutical Co., Ltd. (OTCMKTS:SNPHY) gapped down prior to trading on Wednesday . The stock had previously closed at $12.57, but opened at $11.8390. Santen Pharmaceutical shares last traded at $11.8390, with a volume of 516 shares.

Analyst Ratings Changes

Separately, Zacks Research raised Santen Pharmaceutical to a “hold” rating in a research report on Monday, April 13th. One research analyst has rated the stock with a Hold rating, Based on data from MarketBeat, the stock currently has a consensus rating of “Hold”.

Santen Pharmaceutical Trading Down 4.7%

The firm has a 50-day simple moving average of $11.16 and a two-hundred day simple moving average of $10.82. The company has a market capitalization of $3.86 billion and a price-to-earnings ratio of 0.10.

About Santen Pharmaceutical

Santen Pharmaceutical Co, Ltd. is a Japan‐based specialty pharmaceutical company focused exclusively on ophthalmology. Headquartered in Osaka, Santen engages in the research, development, manufacture and marketing of prescription and over‐the‐counter products for the diagnosis and treatment of eye diseases. Its core product portfolio includes therapies for glaucoma, dry eye, retinal disorders, uveitis and post‐operative care, as well as surgical equipment and diagnostic agents designed to support comprehensive eye care.

With roots tracing back to the late 19th century, Santen has grown from a domestic manufacturer to a global ophthalmic specialist.